Portfolio Lab

Amneal Pharmaceuticals, Inc.

  • Stock
  • Ticker AMRX
  • ISIN US03168L1052
  • Nasdaq

Health care · Pharmaceuticals · USA

$21.12 −1.26%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Amneal Pharmaceuticals, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

AMRXGlobal equities (VT)

$10,000 grew to $14,821. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −94.8% in 03/2023, measured from the peak in 08/2018. The old peak has not been reached again yet.

1-year return
+83.4%
5-year return p.a.
+35.5%
10-year return p.a.
+4.0%
Volatility p.a.
52.8%
Largest decline
−94.8%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue731695725785814723796863
Gross profit263256286274297320335334
Operating income761001117011214213095
EBITDA–––85126––110
Net income-3112222.4356258-22
Earnings per share-0.100.040.070.010.110.190.18-0.06
Balance sheet
Total assets3,5013,3653,4233,6003,6783,5403,7765,267
Liabilities3,6113,4973,5353,7103,7503,5863,7434,736
Equity-109-132-112-109-71-4533531
Cash1115972201282198128157
Long-term debt2,1622,1542,1462,5672,5652,5662,5642,916
Cash flow
Operating cash flow1187.484118130-27-2198
Capital expenditure-15-13-23-12-22-8.2-31-32
Free cash flow103-5.861106109-35-5267

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2023 at +205.0%, weakest 2019 at −64.4%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
9 Nov 2026−$0.06
6 Aug 2026$0.18
7 May 2026$0.19
27 Feb 2026$0.11
6 Nov 2025$0.01
7 Aug 2025$0.07
7 May 2025$0.04
28 Feb 2025−$0.10
12 Nov 2024$0.00
9 Aug 2024$0.02
8 May 2024−$0.30
14 Mar 2024−$0.57

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€6.7bn
Market cap in trading currency
$7.36bn
Enterprise value
$10.1bn
P/E
50.3
P/S
2.30
P/B
13.85
EV/Sales
3.17
EV/EBITDA
–
Earnings yield
2.0%
FCF yield
1.2%

Results (last four quarters)

Revenue
$3.20bn
Gross profit
$1.29bn
EBITDA
–
Net income
$133m
Earnings per share
$0.42
Revenue per share
$9.17
Revenue growth
+10.0%
Earnings growth
−1,015.8%

Profitability

Gross margin
40.2%
Operating margin
15.0%
Net margin
4.2%
Return on equity
25.1%
Return on assets
2.5%

Balance sheet and cash flow

Cash
$157m
Cash per share
$0.45
Financial debt
$2.94bn
Debt/equity %
553
Current ratio
1.87
Book value per share
$1.52
Operating cash flow
$181m
Free cash flow
$88.2m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
348m
Volume
1.66m
Avg. volume 3 months
3.16m
Relative volume
0.5

Price and technicals

Price
$21.12
1 day
−1.3%
52-week high
$21.88
52-week low
$11.52
Distance to 52-week high
−3.5%
Distance to 52-week low
+83.4%
Distance to 50-day line
+4.9%
Distance to 200-day line
+29.8%
RSI (14)
54
Volatility 1M
38.8%

Performance

1 week
−1.2%
1 month
+3.1%
3 months
+18.8%
6 months
+70.0%
YTD
+67.6%
1 year
+83.3%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has AMRX performed since 11/2016?

$10,000 grew to $14,821 by 20 Nov 2026, which is +4.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is AMRX?

Volatility was 52.8% per year, measured on monthly returns. The largest decline from a peak was −94.8%, with the low in 03/2023.

How does AMRX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, AMRX returned +4.0% at 52.8%. The correlation of monthly returns was 0.37; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Amneal Pharmaceuticals, Inc. (AMRX): Return and risk